Diagnostic and therapeutic applications of EndMT-related diseases using SET7 / 9
SET7/9 is utilized as a biomarker and inhibitor to diagnose and treat EndMT-related diseases, particularly pulmonary arterial hypertension, by inhibiting endothelial-mesenchymal transition, enhancing diagnostic efficiency and therapeutic efficacy.
Patent Information
- Application Number
- JP2024532978
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-14
- Filing Date
- 2022-11-16
- Publication Date
- 2024-12-03
AI Technical Summary
Current screening methods for EndMT-related diseases are inefficient and lack effective biomarkers for rapid diagnosis and therapeutic agent identification, particularly for conditions like pulmonary arterial hypertension.
The use of SET7/9 protein or its encoding gene as a biomarker for diagnosing EndMT-related diseases, along with a diagnostic kit and pharmaceutical compositions containing SET7/9 inhibitors to prevent or treat these conditions.
SET7/9 serves as a crucial epigenetic factor in EndMT, enabling rapid diagnosis and therapeutic intervention by inhibiting endothelial-mesenchymal transition, effectively addressing pulmonary vascular diseases such as pulmonary fibrosis and hypertension.
Smart Images

Figure 2024544673000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the diagnostic and therapeutic use of SET7 / 9 for endothelial-mesenchymal transition (EndMT)-associated diseases. [Background technology]
[0002] Endothelial-mesenchymal transition (EndMT) is a general term used to describe the process in which vascular endothelial cells lose their essential properties in response to various external stimuli and become cells with the characteristics of mesenchymal cells that can redifferentiate into cells such as mesenchymal stem cells, smooth muscle cells, and fibroblasts.
[0003] According to research conducted to date on EndMT, it has been reported that endothelial cell fibrosis, together with inflammatory responses, causes or aggravates a series of diseases such as cancer or arteriosclerosis, and much related research is still being conducted regarding the various external stimuli that cause damage to endothelial cells.
[0004] Meanwhile, EndMT has traditionally been known as the cause of fibroblasts and myofibroblasts, which pathologically affect cancer and fibrosis. Recent new research has shown that transformed cells can differentiate into chondroblasts, osteoblasts, and adipoblasts, respectively. However, EndMT research is insufficient compared to epithelial-mesenchymal transition (EMT) research.
[0005] Currently, research and development organizations and companies involved in EndMT-related diseases are making huge investments in related technologies and are working to improve the productivity of these investments. The typical screening process consists of compound dispensing, dilution, mixing of screening components, incubation and detection, analysis of screening data, and reporting of results. Using such a system, millions of libraries are screened to obtain data, but new screening methods are continuously required to screen the libraries more quickly and efficiently against the thousands of active substances that are expected to be derived from detailed research in the future. Summary of the Invention [Problem to be solved by the invention]
[0006] An object of the present invention is to provide a biomarker composition for diagnosing endothelial-mesenchymal transition (EndMT)-related diseases, which comprises, as an active ingredient, a methyltransferase SET7 / 9 protein or a gene encoding the same.
[0007] Another object of the present invention is to provide a composition for diagnosing EndMT-related diseases, which contains as an active ingredient a preparation capable of measuring the expression level of methyltransferase SET7 / 9, and a kit for diagnosing EndMT-related diseases, which contains the composition.
[0008] Another object of the present invention is to provide a method for providing information necessary for diagnosing EndMT-related diseases by measuring the expression level of SET7 / 9 in samples isolated from patients.
[0009] It is still another object of the present invention to provide a method for screening therapeutic agents for EndMT-related diseases by measuring the level of expression or activity of SET7 / 9 in vascular endothelial cells.
[0010] It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, which comprises an inhibitor of SET7 / 9 expression or activity as an active ingredient.
[0011] Yet another object of the present invention is to provide a reagent composition for inhibiting EndMT in pulmonary artery endothelial cells in vitro or in a rat model of pulmonary arterial hypertension in vivo, comprising an inhibitor of SET7 / 9 expression or activity as an active ingredient.
[0012] Yet another object of the present invention is to provide a method for inhibiting EndMT in pulmonary artery endothelial cells or a rat model of pulmonary artery hypertension, comprising the step of treating a SET7 / 9 expression or activity inhibitor to pulmonary artery endothelial cells in vitro or to a rat model of pulmonary artery hypertension in vivo. [Means for solving the problem]
[0013] In order to achieve the above-mentioned objectives, the present invention provides a biomarker composition for diagnosing endothelial-mesenchymal transition (EndMT)-related diseases, which comprises, as an active ingredient, a methyltransferase SET7 / 9 protein or a gene encoding the same.
[0014] The present invention also provides a composition for diagnosing EndMT-related diseases, which comprises, as an active ingredient, a preparation capable of measuring the expression level of methyltransferase SET7 / 9.
[0015] The present invention also provides a kit for diagnosing an EndMT-related disease, comprising the composition for diagnosing an EndMT-related disease.
[0016] The present invention also provides a method for providing information necessary for diagnosing an EndMT-related disease, comprising the steps of: (1) measuring the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein from a sample isolated from a patient; (2) comparing the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein with a control sample; and (3) determining that the disease is an EndMT-related disease if the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein is higher than that of the control sample.
[0017] The present invention also provides a method for screening a therapeutic agent for an EndMT-related disease, comprising the steps of: (1) contacting a test substance with vascular endothelial cells; (2) measuring the level of expression or activity of SET7 / 9 protein in the vascular endothelial cells contacted with the test substance; and (3) selecting a test substance that reduces the level of expression or activity of the SET7 / 9 protein compared to a control sample.
[0018] The present invention also provides a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, which comprises an inhibitor of SET7 / 9 expression or activity as an active ingredient.
[0019] The present invention also provides a reagent composition for inhibiting EndMT in pulmonary artery vascular endothelial cells in vitro or in a rat model of pulmonary arterial hypertension in vivo, comprising an inhibitor of SET7 / 9 expression or activity as an active ingredient.
[0020] The present invention also provides a method for inhibiting EndMT in pulmonary artery endothelial cells or a rat model of pulmonary arterial hypertension, comprising the step of treating pulmonary artery endothelial cells in vitro or in a rat model of pulmonary arterial hypertension in vivo with an inhibitor of SET7 / 9 expression or activity. Effect of the Invention
[0021] The present invention relates to the use of SET7 / 9 in the diagnosis and treatment of endothelial-mesenchymal transition (EndMT)-related diseases. The inventors have confirmed that simultaneous treatment with TGF-β2 and IL-1β is a strong condition for inducing endothelial-mesenchymal transition, that methyltransferase SET7 / 9 is an important epigenetic factor in the process of inducing endothelial-mesenchymal transition, and that inhibition of SET7 / 9 inhibits endothelial-mesenchymal transition by regulating fibrotic signaling. They also revealed that inhibition of SET7 / 9 restores vascular endothelial cell dysfunction caused by endothelial-mesenchymal transition, and that endothelial-mesenchymal transition is closely related to pulmonary vascular diseases. [Brief description of the drawings]
[0022] [Figure 1a-1f] Results show that simultaneous treatment of TGF-β2 and IL-1β in human PAECs induces a robust endothelial-mesenchymal transition (EndMT). [Figures 2a-2i] Results show that the methyltransferase SET7 / 9 is required for changes in endothelial-mesenchymal transition gene expression induced by TGF-β2 and IL-1β. [Diagram 3] Results show that SET7 / 9 regulates profibrotic signaling induced by cotreatment with TGF-β2 and IL-1β. [Figure 4] Our results show that SET7 / 9 is mainly located in the cytoplasm and regulates TGF-βR1 expression through methylation in hPAECs. [Diagram 5] Results show that inhibition of SET7 / 9 ameliorates vascular endothelial cell dysfunction induced by TGF-β2 and IL-1β. [Figure 6] We show that EndMT occurs in pulmonary vascular disease and that SET7 / 9 is significantly upregulated in animal models of pulmonary arterial hypertension and pulmonary fibrosis. [Figure 7] 4 shows the results of recovery of endothelial-mesenchymal transition by the SET7 / 9 inhibitor cyproheptadine. [Figure 8]1 shows the results of the effect of the SET7 / 9 inhibitor cyproheptadine in an animal model of SuHx-induced pulmonary arterial hypertension. [Figure 9] 1 shows the results of recovery of endothelial-mesenchymal transition by the SET7 / 9 specific inhibitor (R)-PFI-2. [Figure 10] 1 shows the results of the effect of the SET7 / 9 specific inhibitor (R)-PFI-2 in an animal model of SuHx-induced pulmonary arterial hypertension. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] The present invention provides a biomarker composition for diagnosing endothelial-mesenchymal transition (EndMT)-associated diseases, which comprises, as an active ingredient, a methyltransferase SET7 / 9 protein or a gene encoding the same. Preferably, the EndMT-related disease may be, but is not limited to, pulmonary fibrosis or pulmonary arterial hypertension.
[0024] The present invention also provides a composition for diagnosing EndMT-related diseases, which comprises, as an active ingredient, a preparation capable of measuring the expression level of methyltransferase SET7 / 9.
[0025] In particular, the preparation capable of measuring the expression level of SET7 / 9 may be, but is not limited to, a primer or probe that specifically binds to the SET7 / 9 gene, an antibody, a peptide, an aptamer, or a compound that specifically binds to the SET7 / 9 protein. Preferably, the EndMT-related disease may be, but is not limited to, pulmonary fibrosis or pulmonary arterial hypertension.
[0026] The present invention also provides a kit for diagnosing an EndMT-related disease, comprising the composition for diagnosing an EndMT-related disease. Meanwhile, the kit of the present invention may include an antibody that specifically binds to the marker component, a secondary antibody conjugate to which a label that develops color upon reaction with a substrate is attached, a chromogenic substrate solution that develops color with the label, a washing solution, and an enzyme reaction stop solution, and may be fabricated in multiple separate packages or compartments containing the reagent components to be used.
[0027] As used herein, the term "diagnosis" includes determining a subject's susceptibility to a particular disease or disorder, determining whether a subject currently has a particular disease or disorder, determining the prognosis of a subject with a particular disease or disorder, or therametrics (e.g., monitoring a subject's condition to provide information regarding the efficacy of a treatment).
[0028] As used herein, the term "primer" refers to a short nucleic acid sequence having a free 3'-hydroxyl group, capable of forming base pairs with a complementary template and acting as an initiation point for copying the template strand. A primer can initiate DNA synthesis in the presence of a polymerization reagent (i.e., DNA polymerase or reverse transcriptase) and four different nucleoside triphosphates at an appropriate buffer solution and temperature. The PCR conditions and the lengths of the sense and antisense primers can be appropriately selected according to techniques known in the art.
[0029] In this specification, the term "probe" refers to a nucleic acid fragment such as RNA or DNA, which can specifically bind to something other than mRNA and corresponds to at least a few bases or at most a few hundred bases, and is labeled so that the presence or absence and expression level of a specific mRNA can be confirmed. The probe can be produced in the form of an oligonucleotide probe, a single strand DNA probe, a double strand DNA probe, an RNA probe, etc. The selection of an appropriate probe and hybridization conditions can be appropriately selected according to techniques known in the art.
[0030] As used herein, the term "antibody" is a term known in the art and refers to a specific immunoglobulin directed against an antigenic site. The antibody in the present invention refers to an antibody that specifically binds to SET7 / 9 of the present invention, and the antibody can be produced according to a conventional method in the art. The form of the antibody includes polyclonal antibodies or monoclonal antibodies, and includes all immunoglobulin antibodies. The antibody refers to a complete form having two full-length light chains and two full-length heavy chains. The antibody also includes special antibodies such as humanized antibodies.
[0031] In this specification, the term "peptide" has the advantage of having a high binding strength to target substances and does not denature even during heat / chemical treatment. In addition, because of its small molecular size, it can be attached to other proteins and used as a fusion protein. Specifically, it can be attached to a polymer protein chain and used as a diagnostic kit and drug delivery material.
[0032] As used herein, the term "aptamer" refers to a type of polynucleotide composed of a special type of single-stranded nucleic acid (DNA, RNA, or modified nucleic acid) that has a stable tertiary structure and is capable of binding to a target molecule with high affinity and specificity. As described above, aptamers can be used in place of antibodies because they are composed of polynucleotides that can specifically bind to antigenic substances like antibodies, and are more stable, have a simpler structure, and are easier to synthesize than proteins.
[0033] The present invention also provides a method for providing information necessary for diagnosing an EndMT-related disease, comprising the steps of: (1) measuring the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein from a sample isolated from a patient; (2) comparing the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein with a control sample; and (3) determining that the disease is an EndMT-related disease if the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein is higher than that of the control sample. Preferably, the EndMT-related disease may be, but is not limited to, pulmonary fibrosis or pulmonary arterial hypertension.
[0034] As used herein, the term "sample isolated from a patient" includes, but is not limited to, samples such as tissues, cells, whole blood, serum, plasma, saliva, sputum, cerebrospinal fluid, or urine that have a difference in expression level of the SET7 / 9 gene or SET7 / 9 protein from a control group.
[0035] In detail, methods for measuring the mRNA expression level include, but are not limited to, RT-PCR, competitive RT-PCR, real-time RT-PCR, RNase protection assay (RPA), Northern blotting, and DNA chips.
[0036] In particular, methods for measuring the expression level of the protein include, but are not limited to, Western blot, ELISA (enzyme linked immunosorbent assay), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, and protein chips.
[0037] The present invention also provides a method for screening a therapeutic agent for an EndMT-related disease, comprising the steps of: (1) contacting a test substance with vascular endothelial cells; (2) measuring the level of expression or activity of SET7 / 9 protein in the vascular endothelial cells contacted with the test substance; and (3) selecting a test substance that reduces the level of expression or activity of the SET7 / 9 protein compared to a control sample.
[0038] The term "test substance" used in referring to the screening method of the present invention means an unknown candidate substance used in screening to test whether it affects the expression level of a gene or whether it affects the expression or activity of a protein. The sample includes, but is not limited to, chemical substances, nucleotides, antisense-RNA, siRNA (small interference RNA), and natural product extracts.
[0039] The present invention also provides a pharmaceutical composition for preventing or treating pulmonary arterial hypertension, which comprises an inhibitor of SET7 / 9 expression or activity as an active ingredient. Preferably, the SET7 / 9 expression or activity inhibitor may be an antisense nucleotide, siRNA (small interfering RNA) and shRNA (short hairpin RNA), compound, peptide, aptamer, and antibody that specifically binds to SET7 / 9, and more preferably, the SET7 / 9 expression or activity inhibitor may be, but is not limited to, (R)-PFI-2.
[0040] The pharmaceutical composition of the present invention may be prepared using pharma- ceutical compatible and physiologically acceptable auxiliary agents in addition to the active ingredient, and the auxiliary agents may be solubilizers such as excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, lubricants, or flavoring agents. The pharmaceutical composition of the present invention may be preferably formulated as a pharmaceutical composition containing one or more pharma- ceutical acceptable carriers in addition to the active ingredient for administration. In the composition formulated into a liquid solution, acceptable pharmaceutical carriers include physiological saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components may be mixed together, as sterile and biocompatible, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be added to the composition to prepare injection preparations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets.
[0041] The pharmaceutical formulation of the pharmaceutical composition of the present invention may be in the form of granules, powders, coated tablets, tablets, capsules, suppositories, syrups, juices, suspensions, emulsions, drops, or injectable liquids, and sustained release formulations of active compounds. The pharmaceutical composition of the present invention may be administered in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intraarterial, intraperitoneal, intrasternal, transdermal, intranasal, inhalation, topical, rectal, oral, intraocular, or intradermal routes. The effective amount of the active ingredient of the pharmaceutical composition of the present invention means the amount required for the prevention or treatment of a disease. Therefore, it may be adjusted according to various factors including the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of formulation, and the patient's age, body weight, general health, sex, and diet, administration time, administration route, and excretion rate of the composition, treatment period, and drugs used simultaneously. For example, but not limited to, in the case of an adult, when administered once to several times a day, the composition of the present invention may be administered at a dose of 0.1 ng / kg to 10 g / kg for a compound, 0.1 ng / kg to 10 g / kg for a polypeptide, protein, or antibody, and 0.01 ng / kg to 10 g / kg for an antisense nucleotide, siRNA, shRNAi, or miRNA.
[0042] The present invention also provides a reagent composition for inhibiting EndMT in pulmonary artery vascular endothelial cells in vitro or in a rat model of pulmonary arterial hypertension in vivo, comprising an inhibitor of SET7 / 9 expression or activity as an active ingredient.
[0043] Preferably, the SET7 / 9 expression or activity inhibitor may be, but is not limited to, cyproheptadine or (R)-PFI-2.
[0044] The present invention also provides a method for inhibiting EndMT in pulmonary artery endothelial cells or a rat model of pulmonary arterial hypertension, comprising the step of treating pulmonary artery endothelial cells in vitro or in a rat model of pulmonary arterial hypertension in vivo with an inhibitor of SET7 / 9 expression or activity.
[0045] Preferably, the SET7 / 9 expression or activity inhibitor may be, but is not limited to, cyproheptadine or (R)-PFI-2. EXAMPLES
[0046] The present invention will be described in detail below with reference to examples to aid in understanding the present invention. However, the following examples are merely for illustrating the contents of the present invention, and the scope of the present invention is not limited to the following examples. The examples of the present invention are provided to more completely explain the present invention to those having average knowledge in the art.
[0047] <Experimental Example> The following experimental examples are provided to provide examples that are commonly applicable to each embodiment of the present invention. 1. Experimental Animals For the bleomycin-induced PF mouse model, 8-week-old C57BL / 6 mice (specific-pathogen-free grade from SaeronBio, Republic of Korea) were used. When the mice were under respiratory anesthesia, 2 U / kg bleomycin (Sigma, B2434) dissolved in 1× sterile phosphate-buffered saline (PBS) was injected intratracheally. Lungs were harvested from the mice 3 weeks after bleomycin treatment.
[0048] The PAH rat model was performed using 8-week-old male Sprague Dawley rats (specific-pathogen-free grade form SaeronBio, Republic of Korea).
[0049] Semaxanib (DC Chemicals, SU5416), dissolved in DMSO and then suspended in buffer (0.5% sodium carboxymethylcellulose, 0.5% sodium chloride, 0.4% Tween-80, and 0.9% benzyl alcohol in deionized water), was injected subcutaneously into rats at 20 mg / kg. Rats were exposed to hypoxic conditions of 10% O2 for 3 weeks. After recovery to normoxic conditions, rats were administered Cyproheptadine (Cayman) or (R)-PFI-2 (DC Chemicals). Cyproheptadine was administered intraperitoneally daily at 5 mg / kg for 2 weeks, and (R)-PFI-2 was administered subcutaneously every 2 days at 10 mg / kg for 3 weeks. Right ventricular systolic pressure (RVSP) was measured, and the rats were sacrificed.
[0050] 2. Cell Culture and Transfection Pulmonary arterial ECs (PAECs) and human umbilical vein ECs (HUVECs) were cultured in EGM-2 (Lonza) supplemented with MycoZap (Lonza) and 1% penicillin-streptomycin (Welgene). Human microvascular ECs (HMVECs) were cultured in EGM-2-MV (Lonza). Lenti-X-293T and MCF7 cells were cultured in Dulbecco's modified Eagle medium (DMEM) (HyClone) containing 10% fetal bovine serum (FBS, HyClone), 1% penicillin-streptomycin (Welgene), and MycoZap (Lonza). All cell lines were cultured at 37°C in a 5% CO2 incubator and grown at 90% confluency.
[0051] 3. Reagents and Drug Treatment TGF-β2 was purchased from Peprotech and dissolved in purified water containing 0.1% bovine serum albumin (BSA). IL-1β was purchased from R&D System and dissolved in 1× PBS containing 0.1% BSA. TGF-β2 (10 ng / ml) and IL-1β (1 ng / ml) were used at the specified time points. PAECs were washed twice with 1× PBS and then treated with the drugs together with EGM-2 (Lonza) supplemented with 10% FBS, 1% penicillin-streptomycin, and MycoZap.
[0052] 4. RNA Extraction and Quantitative Real-time PCR To isolate total RNA, the miRNeasy RNA isolation kit (QIAGEN) was used. The purified RNA was reverse transcribed using the qPCRBIO cDNA Synthesis Kit (PCR-BIOSYSTEMS) and real-time quantitative PCR (qRT-PCR) was performed using the qPCRBIO SyGreen Mix Hi-ROX (PCR-BIOSYSTEMS) according to the manufacturer's instructions. RNA extracts from animal lung tissues were homogenized at 25 Hz for 3 min and dissolved in QIAZOL (provided by the miRNeasy RNA isolation kit). To measure the relative expression of RNA, ribosomal 18S RNA was used as an internal control in vitro and in vivo. The PCR primer sequences used for qRT-PCR are shown in Table 1.
[0053] [Table 1] JPEG2024544673000003.jpg139170
[0054] 5. Immunoprecipitation and Western Blotting All cells were lysed in RIPA (radioimmunoprecipitation assay) buffer (Biosesang) containing protease (GenDepot) and phosphatase (Sigma Aldrich) inhibitors for 20 min, followed by centrifugation at 13,000 rpm for 15 min at 4 °C. Protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Scientific), and an equal amount of protein was boiled with Laemmli SDS Sample Buffer. For immunoprecipitation, cells were lysed in immunoprecipitation buffer (50 mM Tris-HCl (pH 7.4), 50 mM NaCl, 1% Triton X-100, 0.5% NP-40) containing protease (GenDepot) and phosphatase (Sigma Aldrich) for 20 min, followed by centrifugation at 13,000 rpm for 15 min at 4 °C. Agarose beads A / G (Sata Cruz) were added to the cell lysate, and after pre-clearing at 4°C for 1 hour, the mixture was reacted with the antibody overnight at 4°C. Then, 20 ul of agarose beads A / G were added and reacted at 4°C for 2 hours. The mixture was centrifuged, and the resulting pellet was washed several times with immunoprecipitation buffer, and Laemmli SDS Sample Buffer was added and boiled.
[0055] Proteins were separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred to a polyvinylidene difluoride membrane (Millipore). After blocking the membrane with 3% BSA dissolved in 0.2% PBS with TweenR detergent (PBST), the proteins on the membrane were reacted with the primary antibodies listed in Table 2 overnight. For immunodetection, HRP-conjugated secondary antibodies (1:4000) were conjugated with the primary antibodies at room temperature for 1 hour (average temperature 22°C) and then detected using an enhanced chemiluminescence detection system (Thermo Scientific). To separate cytoplasmic and nuclear proteins, the EpiQuik Nuclear Extraction Kit (EpiGentek) was used according to the manufacturer's instructions. Protein extracts from animal lung tissues were homogenized in RIPA buffer at 25 frequency (Hz) for 3 minutes.
[0056] [Table 2] JPEG2024544673000005.jpg30170
[0057] 6. Lentivirus Production and Infection For SET7 / 9 overexpression in PAECs, a SET7 / 9 overexpressing lentivirus vector (provided by Dr. Kim Geun-il, Sookmyung Women's University) was used. Lenti-X-293T was used to produce lentivirus, which was transfected with lentivirus vectors together in a second-generation packaging system (psPAX2 and pCL-VSVG) using a polyethyleneimine (PEI) transfection reagent. 48 hours after cells were transfected, the medium containing lentivirus was harvested and replaced with fresh complete medium for another 24 hours. The harvested lentivirus was concentrated using an Amicon Centrifugal Filter Unit (Milipore) and quantified using a qPCR Lentivirus Titration Kit (Abmgood, LV900). PAECs were infected with SET7 / 9 overexpressing lentivirus (100 multiplicity of infection [MOI]) in serum-free medium. After 24 hours, the medium was replaced with fresh complete medium. The process was repeated a total of two times (total infection time 96 hours).
[0058] 7. Immunocytochemistry PAECs and Lenti-X-293T were fixed with 4% formaldehyde and washed with 1x PBS. Cells were then permeabilized with 0.2% Triton X-100 and blocked with 1% BSA in 1x PBS at room temperature for 1 hour. Cells were incubated overnight at 4°C with the following primary antibodies: Anti-VE-cadherin (Cell Signaling, 2500S, 1:100), anti-Fibronectin (BD Pharmigen, 61007, 1:100), anti-TAGLN (Abcam, ab14106, 1:200), anti-α-SMA conjugated with Cy3 (Sigma Aldrich, C6198, 1:200), anti-NF-κB p65 (Cell Signaling, 8242S, 1:400), anti-SET7 / 9 (LsBio, C337450, 1:100), and rhodamine phalloidin (Sigma Aldrich, 1:1000). Donkey anti-goat Alexa Fluor 488 and donkey anti-goat Alexa Fluor 568 (Invitrogen, 1:400) secondary antibodies were incubated at room temperature for 1 h. To obtain immunostaining images, a confocal microscope equipped with a 60× objective lens (Zeiss LSM-700) was used.
[0059] 8. Immunohistochemistry The lung tissues of the collected animals were embedded in paraffin blocks and then cut at 10 μm. Paraffin sections were deparaffinized using Histoclear for 10 minutes. To hydrate the sections, gradients of ethanol in pure water were used (100%, 90%, 70%, 50%, 30%, and 0%). The tissue slides were placed in Borg Decloaker RTU antigen retrieval solution (Biocare Medical), and the sections were heated using a pressure cooker to retrieve antigens. When the temperature of the retrieval solution had cooled, the sections were washed three times with 1×PBS for 5 minutes each, and then blocked with blocking buffer (1% BSA and 5% goat serum dissolved in 1×PBS) for 30 minutes at room temperature. The sections were reacted with primary antibodies at 4°C overnight. Anti-vWF conjugated with FITC (Abcam, ab8822, 1:50), anti-α-SMA conjugated with Cy3 (Sigma Aldrich, C6198, 1:100), anti-SM22α (Abcam, ab14106, 1:130), and anti-SET7 / 9 (LsBio, C337450, 1:50) were used. For fluorescent staining, the sections were incubated with donkey anti-goat Alexa Fluor 568 (Invitrogen, 1:150-1:400), goat anti-rabbit Alexa Fluor 647 (Invitrogen, 1:150), and donkey anti-goat Alexa Fluor 568 (Invitrogen, 1:400) secondary antibodies at room temperature for 1 h. For color staining, the cells were incubated overnight with primary antibodies, followed by incubation with Goat anti-Mouse IgG secondary antibody, HRP (Pierce, 1:100) for 1 hour, and then color reacted using a DAB staining kit (Vector, SK-4800). Hematoxylin and eosin staining was performed using staining products from Vector. Image analysis was performed using Zeiss and Leica confocal microscopes equipped with a 40× objective lens. The colocalization effect was verified by MOC (Mander's overlap coefficient).
[0060] 9. Cell migration analysis PAEC migration assays were performed using 12-well plates containing SPLScar Block (SPL) according to the manufacturer's instructions. Cells were cultured in EGM-2 supplemented with 10% FBS, 1% penicillin-streptomycin, and MycoZap and treated with the respective drugs. Migration assays in response to drug treatment were performed and observed under a light microscope. Migration completion was analyzed using Image J software.
[0061] 10. Dextran Permeation Analysis PAECs were cultured at 2 × 10 per well of a 24-well plate with cell culture inserts (SPL, 0.4 μm). 5 After drug treatment, the inserts were transferred to wells containing serum-free media (SFM), and the media in the inserts was replaced with SFM containing FITC-dextran (Sigma Aldrich, FD40S, 1 mg / ml). After 10 minutes and 1 hour, a portion of the SFM from the plate wells where dextran penetration had occurred was removed and the fluorescence was measured. The fluorescence intensity was measured on a microplate reader (excitation, 485 nm; emission, 530 nm).
[0062] 11.Dil-Ac-LDL absorption analysis PAECs were cultured at 2 × 10 per well of a 12-well plate. 5 After drug treatment, the cells were reacted with Dil-Ac-LDL (Invitrogen, 10 μg / ml) at 37° C. for 3 hours. After reaction, the cells were washed 4 times with 1× PBS and then imaged under a fluorescent microscope.
[0063] 12.Statistical analysis All experimental data were analyzed after performing at least three experiments and verified using GraphPad Prism 5.0 and 7.0 software. Statistical differences were analyzed by unpaired two-tailed Student's t-test for comparing two groups. When there were three or more groups, they were analyzed by One-way ANOVA. A p-value <0.05 was considered to indicate statistical significance.
[0064] <Example 1> Simultaneous treatment with TGF-β2 and IL-1β, which is a potent induction condition for endothelial-mesenchymal transition (EndMT) To investigate whether co-treatment with TGF-β2 and IL-1β is a potent inducer of endothelial-mesenchymal transition, we compared the extent of endothelial-mesenchymal transition between the two drugs, either individually or simultaneously. Western blot (Figure 1A) and qRT-PCR (Figure 1B) showed that the vascular endothelial cell markers CD31 (PECAM1) and VE-cadherin (CDH5) were decreased more in the group treated with both drugs than in the group treated with each drug alone. The mesenchymal cell markers Fibronectin (FN), N-cadherin (CDH2), SM22α (TAGLN), MMP2, and SNAIL were also increased more in the group treated with both drugs simultaneously. When endothelial-mesenchymal transition occurs, vascular endothelial cells lose their unique characteristic of a cobblestone-like shape and change to a long, spindle-shaped morphology resembling that of mesenchymal cells. By staining with phalloidin, which binds to F-actin, we confirmed that changes in cell morphology and cytoskeleton occurred in pulmonary artery endothelial cells (PAECs) that underwent endothelial-mesenchymal transition due to simultaneous treatment with TGF-β2 and IL-1β (Figure 1C). When the degree of endothelial-mesenchymal transition was compared when TGF-β2 and IL-1β were treated simultaneously for 1, 3, 5, and 7 days, the changes in protein expression of mesenchymal cell markers, except for SNAIL, increased over time (Figure 1D). The mRNA expression of mesenchymal cell markers also increased over time, but CDH2 and SNAIL were highest in the 1-day treatment group and showed a tendency to gradually decrease thereafter (Figure 1E). Both the mRNA and protein expression of vascular endothelial cell markers gradually decreased over time (Figures 1D and 1E). Immunocytochemical staining showed that under endothelial-mesenchymal transition induction conditions using simultaneous treatment with TGF-β2 and IL-1β, the results were identical to those of protein and RNA (Figure 1F).
[0065] Example 2: Methyltransferase SET7 / 9, an important epigenetic factor in the induction process of endothelial-mesenchymal transition To search for epigenetic factors that change significantly under the endothelial-mesenchymal transition conditions induced by TGF-β2 and IL-1β, we used RT2 Profiler PCR Arrays. Analysis using scatter plot graphs and heat maps revealed that SET7 / 9 was a promising candidate factor. Western blot (Figure 2A), qRT-PCR (Figure 2B), and immunocytochemical staining (Figure 2C) experiments showed that SET7 / 9 protein and mRNA expression increased in pulmonary artery endothelial cells in which endothelial-mesenchymal transition was induced by simultaneous treatment with TGF-β2 and IL-1β, which was consistent with the results of the epigenetic factor array. Next, to investigate the relationship between endothelial-mesenchymal transition and SET7 / 9, we observed the effect of SET7 / 9 knockdown. Phalloidin staining confirmed that SET7 / 9 knockdown reduced the degree of cell phenotype change caused by TGF-β2 and IL-1β-induced endothelial-mesenchymal transition (Figure 2D). Western blot (Figure 2E) and qRT-PCR (Figure 2F) confirmed that SET7 / 9 knockdown restored the protein and mRNA expression of endothelial-mesenchymal transition markers. SET7 / 9 overexpression changed the shape of vascular endothelial cells to a morphology similar to that of mesenchymal cells (Figure 2G), and the protein and mRNA expression of endothelial-mesenchymal transition markers also changed (Figures 2H and 2I).
[0066] Example 3: Inhibition of SET7 / 9 that regulates fibrotic signaling and inhibits endothelial-mesenchymal transition To investigate the downstream signaling pathways of endothelial-mesenchymal transition, we investigated TGF-β-SMAD2 / 3 and NF-κB signaling, which are representative pro-fibrotic signaling pathways. We examined whether SET7 / 9 regulates SMAD2 / 3 signaling induced by TGF-β2 alone and by co-treatment with TGF-β2 and IL-1β. As a result, we confirmed that phosphorylated SMAD2 / 3 was increased more in the TGF-β2 and IL-1β co-treatment group than in the TGF-β2 alone treatment group, and that this signaling was inhibited by SET7 / 9 knockdown (Figure 3A). We also confirmed that overexpression of SET7 / 9 increased the phosphorylation of SMAD2 / 3 (Figure 3B). Next, we confirmed by immunocytochemical staining that the expression of p65, which was increased by co-treatment with TGF-β2 and IL-1β, was reduced by SET7 / 9 knockdown (Figure 3C). Cytoplasmic and nuclear fractionation confirmed that simultaneous treatment with TGF-β2 and IL-1β increased the expression of phosphorylated IκBα in the cytoplasm and led to accumulation of NF-κB in the nucleus, both of which were rescued by SET7 / 9 knockdown (Fig. 3D).
[0067] Because research results showed that SET7 / 9 is mostly located in the cytoplasm rather than the nucleus, we fractionated SET7 / 9 into the nucleus and cytoplasm in five cell types, PAEC, HUVEC, HMVEC, 293T, and MCF7, and confirmed its expression. As a result, endothelial cells showed higher expression in the cytoplasm than in the nucleus compared with 293T and MCF7 (Figure 4A and Figure 4B). We confirmed whether the K / RS / T / AK motifs recognized and methylated by SET7 / 9 exist in proteins related to canonical TGF-β-SMAD2 / 3 and NF-κB signaling (Figure 4C). Among these, the expression of TGF-βR1 was increased during induction of endothelial-mesenchymal transition and was regulated by SET7 / 9 knockdown (Figure 4D). We also confirmed that overexpression of SET7 / 9 increased the protein expression of TGF-βR1 (Figure 4E). To clarify that TGF-βR1 is a target protein of SET7 / 9, we performed immunoprecipitation and first confirmed that SET7 / 9 and TGF-βR1 bound to each other at the endogenous level (Fig. 4F). To confirm that TGF-βR1 is methylated by SET7 / 9, we overexpressed SET7 / 9 wild type (WT) and mutant type (MT) in which amino acids important for methylation were mutated, and immunoprecipitated with a methylation antibody. As a result, we confirmed that TGF-βR1 methylation was significantly reduced in the group overexpressing the SET7 / 9 mutant type (MT) (Fig. 4G).
[0068] Example 4: Inhibition of SET7 / 9 restores vascular endothelial cell dysfunction caused by endothelial-mesenchymal transition To confirm the role of SET7 / 9 in endothelial cell dysfunction, we performed permeability, migration, and Dil-Ac-LDL uptake experiments. We confirmed that the degree of permeability increased by endothelial-mesenchymal transition induction was restored by SET7 / 9 knockdown (Figure 5A). SET7 / 9 knockdown also reduced the migration of endothelial cells (Figure 5B). The induction of endothelial-mesenchymal transition reduces the ability of endothelial cells to absorb lipoproteins, which was restored by SET7 / 9 knockdown (Figure 5C).
[0069] Example 5: Endothelial-mesenchymal transition closely related to pulmonary vascular disease To confirm the relationship between endothelial-mesenchymal transition and pulmonary vascular disease, we used animal models of pulmonary fibrosis and pulmonary arterial hypertension. In the lung tissue of a mouse model of bleomycin-induced pulmonary fibrosis, hematoxylin-eosin staining (H&E) and Masson's trichrome staining (MTS) confirmed that collagen and connective tissue were increased (Figure 6A and Figure 6B). In the lung tissue of bleomycin-induced mice, the protein and mRNA expression of mesenchymal cell markers was increased (Figure 6C and Figure 6D). Using immunohistochemical staining, we confirmed that the bleomycin group had an increased area where endothelial-mesenchymal transition had occurred, where the vascular endothelial cell marker vWF and the mesenchymal cell marker α-SMA were stained simultaneously (Figure 6E). In addition, in the bleomycin group, the protein and mRNA expression of SET7 / 9 was increased, as confirmed by immunofluorescence staining (Figure 6F) and Western blot and qRT-PCR (Figure 6G).
[0070] We used the Sugen / hypoxia (SuHx) rat model as an animal model of pulmonary arterial hypertension, and confirmed by Western blot that mesenchymal cell markers were significantly increased in lung tissue from the SuHx group (Figure 6H). In addition, we confirmed that the expression of SET7 / 9 was increased in blood vessels using two immunohistochemical staining methods (Figure 6I and Figure 6J).
[0071] Example 6: Restoration of endothelial-mesenchymal transition by the SET7 / 9 inhibitor cyproheptadine Cyproheptadine is a drug that has been reported to have an inhibitory effect on SET7 / 9. To confirm the inhibitory effect of the drug on endothelial-mesenchymal transition, a model was used in which pulmonary artery endothelial cells were simultaneously treated with cyproheptadine together with TGF-β2 and IL-1β for 5 and 7 days. As a result, it was confirmed by Western blot (Figure 7A) and qRT-PCR (Figure 7B) that the expression of endothelial cell markers CD31 (PECAM1) and VE-cadherin (CDH5), and mesenchymal cell markers Fibronectin (FN), N-cadherin (CDH2), SM22α (TAGLN), and SNAIL was restored. In the cyproheptadine-treated group, it was confirmed by phalloidin staining that the cytoskeleton changes, which are characteristic of endothelial-mesenchymal transition, were reduced (Figure 7C). We confirmed that cyproheptadine rescued the endothelial cell dysfunction caused by endothelial-mesenchymal transition, i.e., increased permeability (Fig. 7D) and decreased Dil-Ac-LDL absorption (Fig. 7E). Cyproheptadine rescued the expression of TGFβR1, which was increased by endothelial-mesenchymal transition induction, and reduced the phosphorylation level of the downstream signaling molecule SMAD2 / 3 (Fig. 7F).
[0072] Example 7: Effect of the SET7 / 9 inhibitor cyproheptadine in an animal model of SuHx-induced pulmonary arterial hypertension When cyproheptadine was administered intraperitoneally at a concentration of 5 mg / kg for 2 weeks to rats with SuHx-induced pulmonary arterial hypertension, it was confirmed that right ventricular systolic pressure (RVSP mmHg), right ventricle / left ventricle + septum ratio (RV / LV+S%), and right ventricular weight (RV mg) were reduced (Figure 8A-C). Immunohistochemical staining revealed that muscularization was observed in blood vessels of approximately 50 μm in size in the lung tissue of SuHx rats, and that the degree of muscularization was reduced when cyproheptadine was administered. In SuHx lung tissue, the phenomenon of endothelial-mesenchymal transition, in which endothelial cell and mesenchymal cell markers are stained simultaneously, was increased, and in blood vessels in which such a phenomenon occurred, the expression of SET7 / 9 was observed to increase. However, in the cyproheptadine-treated group, the expression of SET7 / 9 in blood vessels was decreased, and the area of co-staining of endothelial and mesenchymal cell markers was decreased, confirming that endothelial-mesenchymal transition was inhibited (Figure 8D). H&E staining confirmed that the obstructed or enlarged blood vessels in the lung tissue of the cyproheptadine-treated rat group were reduced compared to the SuHx-induced pulmonary arterial hypertension group (Figure 8E). In the lung tissue of the cyproheptadine-treated rat group, the expression of mesenchymal cell markers such as N-cad and SM22α and TGFβR1, a target protein of SET7 / 9, were decreased, and the expression of phosphorylated SMAD2 protein was significantly decreased (Figure 8F).
[0073] Example 8: Restoration of endothelial-mesenchymal transition by SET7 / 9 specific inhibitor (R)-PFI-2 (R)-PFI-2 is a substrate competitive inhibitor that acts by binding to the substrate peptide binding groove of SET7 / 9. Therefore, to confirm the effect of (R)-PFI-2, a specific inhibitor of SET7 / 9, in restoring endothelial-mesenchymal transition, we used a model in which pulmonary artery endothelial cells were simultaneously treated with TGF-β2, IL-1β, and (R)-PFI-2. As a result, we confirmed by Western blot (Figure 9A) that the expression of endothelial cell marker CD31 and mesenchymal cell markers TNC, FN, Calponin, and SM22α was restored, and by qRT-PCR (Figure 9B) that the expression of endothelial cell marker PECAM1 and mesenchymal cell markers FN, CDH2, and COL3A1 was restored. Phalloidin staining confirmed that (R)-PFI-2 reduced cytoskeletal changes (Fig. 9C) and restored permeability (Fig. 9D) and Dil-Ac-LDL uptake capacity (Fig. 9E).
[0074] Example 9: Effect of SET7 / 9 specific inhibitor (R)-PFI-2 in an animal model of SuHx-induced pulmonary arterial hypertension To confirm the effect of (R)-PFI-2 in an animal model, (R)-PFI-2 was administered subcutaneously at a concentration of 10 mg / kg for 3 weeks to rats with SuHx-induced pulmonary arterial hypertension. In the (R)-PFI-2-administered group, it was confirmed that the right ventricular systolic pressure (RVSP mmHg), the right ventricle / left ventricle + septum ratio (RV / LV+S%), and the right ventricular weight (RV mg) were reduced (Figure 10A-C). Immunohistochemical staining showed that the muscularization of blood vessels in lung tissue of SuHx rats was significantly reduced when (R)-PFI-2 was administered. In addition, in SuHx lung tissue, it was observed that the expression of SET7 / 9 in blood vessels in which endothelial-mesenchymal transition had occurred was high, but in the (R)-PFI-2-administered group, the expression of SET7 / 9 in blood vessels was reduced, and the area of simultaneous staining of endothelial cell and mesenchymal cell markers was reduced, confirming that endothelial-mesenchymal transition was inhibited (Figure 10D). H&E staining confirmed that obstructed or enlarged blood vessels in lung tissues of the (R)-PFI-2-administered rat group were reduced compared to the SuHx-induced pulmonary arterial hypertension group (Figure 10E). In lung tissues of the (R)-PFI-2-administered rat group, the expression of mesenchymal cell markers such as Twist and pVIM and TGFβR1, a target protein of SET7 / 9, was reduced, and the expression of phosphorylated SMAD2 protein was significantly reduced (Figure 10F).
[0075] Although certain parts of the present invention have been described in detail above, it is clear to those skilled in the art that such specific descriptions are merely preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the true scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A biomarker composition for diagnosing an endothelial-mesenchymal transition (EndMT)-associated disease, comprising a methyltransferase SET7 / 9 protein or a gene encoding the same as an active ingredient.
2. The biomarker composition for diagnosing an EndMT-related disease according to claim 1, wherein the EndMT-related disease is pulmonary fibrosis or pulmonary arterial hypertension.
3. A composition for diagnosing an EndMT-related disease, comprising, as an active ingredient, a preparation capable of measuring the expression level of methyltransferase SET7 / 9.
4. The composition for diagnosing EndMT-related diseases described in claim 3, characterized in that the preparation capable of measuring the expression level of SET7 / 9 is a primer or probe that specifically binds to the SET7 / 9 gene, an antibody, peptide, aptamer, or compound that specifically binds to the SET7 / 9 protein.
5. The composition for diagnosing an EndMT-related disease according to claim 3, wherein the EndMT-related disease is pulmonary fibrosis or pulmonary arterial hypertension.
6. A kit for diagnosing an EndMT-related disease, comprising the composition according to any one of claims 3 to 5.
7. A method for providing information necessary for diagnosing an EndMT-related disease, comprising the steps of: (1) measuring the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein from a sample isolated from a patient; (2) comparing the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein with a control sample; and (3) determining that the disease is an EndMT-related disease if the mRNA expression level of the SET7 / 9 gene or the expression level of the SET7 / 9 protein is higher than that of the control sample.
8. The method for providing information necessary for diagnosis of an EndMT-associated disease according to claim 7, wherein the EndMT-associated disease is pulmonary fibrosis or pulmonary arterial hypertension.
9. A method for screening a therapeutic agent for an EndMT-related disease, comprising the steps of: (1) contacting a test substance with vascular endothelial cells; (2) measuring the level of expression or activity of SET7 / 9 protein in the vascular endothelial cells contacted with the test substance; and (3) selecting a test substance that reduces the level of expression or activity of the SET7 / 9 protein compared to a control sample.
10. The method for screening a therapeutic agent for an EndMT-related disease according to claim 9, wherein the EndMT-related disease is pulmonary fibrosis or pulmonary arterial hypertension.
11. A pharmaceutical composition for preventing or treating pulmonary arterial hypertension, comprising an inhibitor of SET7 / 9 expression or activity as an active ingredient.
12. The pharmaceutical composition for preventing or treating pulmonary arterial hypertension according to claim 11, wherein the SET7 / 9 expression or activity inhibitor is (R)-PFI-2.
13. A reagent composition for inhibiting EndMT in pulmonary artery vascular endothelial cells in vitro or in a rat model of pulmonary arterial hypertension in vivo, comprising an inhibitor of SET7 / 9 expression or activity as an active ingredient.
14. The reagent composition for inhibiting EndMT according to claim 13, wherein the SET7 / 9 expression or activity inhibitor is cyproheptadine or (R)-PFI-2.
15. A method for inhibiting EndMT in pulmonary artery endothelial cells or a rat model of pulmonary artery hypertension, comprising the step of treating pulmonary artery endothelial cells in vitro or treating a rat model of pulmonary artery hypertension in vivo with an inhibitor of SET7 / 9 expression or activity.
16. The method for inhibiting EndMT according to claim 15, wherein the SET7 / 9 expression or activity inhibitor is cyproheptadine or (R)-PFI-2.
